Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B019 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06970496Phase 1Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD22 CAR-T in B-cell non-Hodgkin lymphoma (B-NHL). Primary endpoints: Dose-limiting toxicity at 2 years and Maximum tolerated dose at 2 years. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
CD19/CD22 CAR-T
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT06970496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970496.